The risk of cardiovascular events (CVE) with alendronate use in real-world hip fracture patients is unknown. This study aimed to investigate the risk of CVE with and without use of alendronate in patients with hip fracture. We conducted a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority.
Introduction
Hip fracture is a common condition that leads to great morbidity and mortality in the elderly population. One of the consequences of hip fracture is an increased risk of cardiovascular events (CVE) such as MI, (1) stroke, (2) and cardiovascular mortality. (3, 4) Thus, there is a clinical need to be aware of this increased risk of CVE among patients who sustain a hip fracture, and to intervene to reduce these life-threatening outcomes.
Nonetheless there are no clinical recommendations that address this issue.
Nitrogen-containing bisphosphonates (N-BPs) are the recommended treatment for the secondary prevention of fractures in persons who have sustained a fragility fracture (5) .
However, N-BPs are under-used worldwide due to patients' concerns about potential side effects. (6) Emerging evidence has suggested that N-BPs are potential cardiacprotecting agents. (7, 8) A longitudinal cohort study in women showed an association of N-BPs and decreased prevalence of cardiovascular calcification in older subjects.
Another randomized clinical trial demonstrated that treatment with alendronate inhibited the progression of aortic calcification after kidney transplant, compared with no treatment of bisphosphonates. (8) Animal studies found that farnesyl pyrophosphate synthase (FPPS), the molecular target of N-BPs, is involved in the pathogenesis of cardiac hypertrophy. Cardiac-specific over-expression or inhibition (using alendronate) of FPPS in mice has been shown to result in (9) or attenuate (10) cardiac hypertrophy, respectively.
While the risk of all-cause mortality was reduced by 10-60% in patients treated with NBPs after hip fracture, (11-13) the risk of CVE was inconclusive. A previous randomized controlled trial (RCT) and cohort study showed a trend towards reduction of cardiovascular mortality in patients treated with zoledronate (4) or risedronate (14) following a hip fracture. A recent meta-analysis of RCTs reported a lower risk of cardiovascular mortality in the use of bisphosphonates, although not statistically significant. (11) In view of these findings, further studies are needed to evaluate the role of anti-osteoporosis medication in CVE. (15) Because RCT data are limited with regard to CVE outcomes and participants in clinical trials are rarely representative of the actual patient population receiving medications, large observational studies that include methods to minimize confounding by indication may add important data complementing the randomized trials.
This population-based cohort study used data from a large territory-wide healthcare database to determine the risk of CVE in patients with hip fracture, with and without use of alendronate.
Materials and Methods

Methods
The study protocol was approved by the institutional review boards of the University of Hong Kong and Hong Kong HA.
Data source
Data was collected from the Clinical Data Analysis and Reporting System (CDARS),
an electronic medical database managed by the Hong Kong HA. HA is a public healthcare provider that manages 42 hospitals and institutions, and 120 out-patient clinics, serving >80% of hospital admissions in Hong Kong. CDARS is a centralized database developed for the purposes of research and audit. It includes records of demographics, admission, prescription, diagnosis, procedures, laboratory tests, and deaths. All records are anonymized. The database has been widely used in conducting high-quality population-based studies (16, 17) and is specifically validated for study of the effects of medication on bone fractures. (18) More information about Hong Kong HA is provided in the Supplemental Methods.
Study cohort
This was a retrospective cohort study. We identified patients aged≥50 years who were admitted via an emergency room between January 1 2005 and December 31 2013 with a new diagnosis of hip fracture (ICD-9, 820.XX). Patients who survived and were discharged were included in the study cohort. To reduce selection bias and/or competing risk of death, we excluded patients who fulfilled any of the following criteria: i) previous exposure to anti-osteoporosis medications two-year preceding the index date;
ii) length of stay (LOS) in hospital>60 days (Supplemental Methods). Patients with a longer length of stay may be less healthy and unable to take anti-osteoporosis medications. Inclusion of these patients could lead to substantial selection bias; and iii)
history of cancer where anti-resorptive agents are often prescribed.
Exposure and outcomes
The primary drug of interest was alendronate, which is the first-line therapy for osteoporosis, following hospital discharge post-fracture. Patients were classified as "alendronate-treated" if they had at least one prescription record of alendronate before the end of the study (November 6 2016). Bisphosphonates can accumulate in the skeleton (19) and studies have reported a residual effect of alendronate after treatment withdrawal for up to 7 years (20, 21) . Therefore, once being treated, the patients were considered exposed to the drug until the end of follow-up. In a secondary analysis, we aimed to determine whether the association was also observed for all N-BPs as a single group (including alendronate, ibandronate, risedronate, and zoledronate), and for two anti-osteoporosis medications with different mechanism-of-actions commonly prescribed in Hong Kong (>1% usage among hip fracture patients), namely strontium ranelate and salcatonin.
Primary outcomes of interest were cardiovascular mortality, incident MI, and stroke during the follow-up period. Our previous studies validated the coding of MI and stroke in CDARS with a positive predictive value (PPV) of 85.4% and 91.1% respectively.
In the analysis of incident CVE, patients with outcomes of interest at baseline were excluded. All outcomes were defined by ICD-10 and ICD-9 and are shown in the (Supplemental Table 1 and Table 2 ).
Statistical analysis
The statistical analyses were conducted by two co-authors (C.W.S. and A.Y.S.W.)
independently and cross-checked for quality assurance. Continuous variables are presented as mean±standard deviation (SD) and categorical variables as percentages.
Incident rates per 10,000 person-years and the 95% confident intervals (CIs) for CVE were estimated using a Poisson distribution.
Time-to-event analysis was used to evaluate the association of anti-osteoporosis medication with outcomes. Since there may have been a delay in prescribing alendronate, immortal time bias was possible. Such bias, which would favor the treatment group, has been discussed elsewhere. (22, 23) To address this issue, a timedependent propensity score matching was used (24, 25) , which matches a patient treated at time t (defined as number of days from the date of discharge to first treatment) to
another patient who had not received treatment yet at time t based on the propensity score (PS) at time t. The matched pair was followed from time t until the occurrence of an event, switch to another anti-osteoporosis medication, death, or study end (November 6 2016), whichever occurred first. Using this approach, treated and nontreated groups were followed at the same starting point (time t), which has been shown to be a superior approach to control immortal time bias. (26) As exposure to treatment is time-dependent, propensity scores at different time points were estimated using Cox regression with time-dependent covariates. Details are provided in Supplemental
Methods and the list of covariates used in the PS model is shown in Supplemental Table   2 . Each treated patient was matched with up to 3 non-treated patients using sequential greedy matching with a caliper of 0.2 standard deviation. Those who failed to match with a non-treated patient were excluded. To assess the quality of matching, absolute standardized differences (ASD) in covariates between treatment groups were estimated.
After matching, all covariates had an ASD <0.25 ( Table 1 ), indicating that the covariates were well balanced (27) . 
Results
Baseline characteristics
Between January 1 2005 and December 31 2013, 46,253 patients aged ≥50 years were admitted via the emergency room with a new diagnosis of hip fracture. The top three causes of mortality in the first year following hip fracture are shown in Figure 1 . The risk of cardiovascular mortality was the highest in the first month after hip fracture (22.2%), and dropped to 11.6% after one year. Nonetheless, risk of pneumonia-and cancer-mortality increased continuously.
Among 34,991 patients included in the final cohort (Figure 2 ), 2,868 (8.2%) were prescribed anti-osteoporosis medication in the first year, and 4,602 (13.2%, treated group) by study end date. The mean age of the cohort was 82±9.3 years and 24,337 patients (69.6%) were female. After PS-matching, 4,594 patients in the treatment group were matched with 13,568 non-exposed patients. The median (interquartile range, IQR)
follow-up times in non-exposed and treated groups were 1,076 (1,349) days and 1,446
(1,371) days, respectively. Among the treated patients, 3,081 patients (67.1%) exposed to alendronate (98% of patients treated weekly and 2% treated daily). Of these alendronate-treated patients, over 60% were prescribed the drug in the first year with a mean±SD starting time of 100 (93.5) days after hip fracture. Compared to those patients who were not on treatment, the patients receiving treatment was not associated with better physical functioning or survival prospect, with an odds ratio of 1.01 (95% CI:
0.41-2.50); P=0.98. Survival curves of alendronate treatment and risk of CVEs are presented in Figure 3 .
Alendronate and risk of CVE
At one-year follow up, the incidence of cardiovascular mortality was 108.9 and 34.7
per 10,000 patient-years for the non-treated and alendronate-treated groups, respectively ( Table 2) Table 2 ). The protective association of alendronate and CVEs declined over time but remained statistically significant.
Sensitivity analyses, (Supplemental Table 3 and Table 4 ) revealed similar findings. In a subgroup analysis of only, women, BP use was associated with a reduced risk of cardiovascular mortality and incident MI, in a trend similar to the primary analysis, whereas in men there was association with cardiovascular mortality but not with incident MI. For incident stroke, association was not observed in both sex. (Table 4) ,
Other anti-osteoporosis medications and risk of CVE
In a secondary analysis, similar but statistically more significant findings were observed for all N-BPs exposures (Table 2) . Salcatonin had no association with CVEs at oneyear follow up (Table 3 ) but significant increased risks of incident MI at 5-years (HR 2.0; 95% CI: 1.16-3.46; P=0.013) and at 10-years follow up were observed (HR 2.0;
95% CI: 1.17-3.41; P=0.011). Strontium ranelate showed no association with CVEs.
Sensitivity analysis revealed similar findings (Supplemental Table 3 and Table 4 ).
Discussion
This is the first population-based study using a large electronic clinical patient record database to examine the risk of major CVE in hip fracture patients with and without alendronate treatment. Patients prescribed alendronate treatment versus non-treatment had a significantly reduced risk of CVE. The association could endure for ten years after fracture and was robust in various sensitivity analyses. Nonetheless, it appeared that the protective association was not evident for other classes of anti-osteoporosis treatment.
Hip fracture is often under-treated with anti-osteoporosis medication, which is the worldwide experience. In the current study, only 13.2% of patients received antiosteoporosis medication following hip fracture. Notably, we showed that post-hip fracture use of alendronate reduced cardiovascular mortality. This highlights the importance of initiating alendronate treatment after hip fracture.
Our findings were contrary to some studies where anti-osteoporosis treatment was associated with an increased CVE risk, one of the reasons for the "Crisis in the Treatment of Osteoporosis".
(29) Treatment with bisphosphonates has been associated with an increased risk of MI in patients with a history of fracture. (30) The population in that study was mainly male veterans (>95%), which could explain the discrepancy with our results. Indeed, the current study showed increased risk of incident MI in men but the association was not significant probably due to the relatively small numbers of men in the cohort.
A recent meta-analysis of RCTs on treatment of bisphosphonates reported a decreased risk of cardiovascular mortality but the association was not significant (pooled risk ratio:
0.81; 95% CI 0.64-1.02).
(11) The magnitude of effect sizes that we observed differed from those reported in the RCTs. Overestimation of treatment effect in PS-based observational studies is commonly reported.
(31, 32) One possible reason for the discrepancy is the difference in the study populations. In the meta-analysis, four out of ten trials targeted patients with cancer, whereas our cohort excluded these patients.
Nevertheless, although PS matching has minimized the confounding in observational studies, selection bias due to unmeasured factors may still exist. For example, we cannot evaluate drug adherence by the patients, which is a common limitation of health care database research. Therefore, bias due to a "healthy adherer effect" (33) cannot be ruled out. In RCTs, intention-to-treat analysis is a common approach to address bias due to participants being lost-to follow up. However, some reviews suggested that this approach might underestimate treatment effect, resulting in larger discrepancies between RCTs and observational studies. (34, 35) On the other hand, no association of treatment and incident MI was shown in the meta-analysis. The studies included in the meta-analysis had different follow up periods ranging from 1 to 15 years. However, the current study showed that the protective association of treatment and CVEs declined over time. Such findings suggest that the studies with long follow-up periods in the meta-analysis may dilute the association, leading to the discrepancy of findings between the meta-analysis and the current study.
One RCT of zolendronate showed reduction of mortality after hip fracture only after the first year, (36) which was contrary to our findings. In the current study, most of the patients were treated with alendronate while only small number of cases were treated with other N-BPs. We cannot rule out the possibility that the protective association of alendronate and other N-BPs on the risk of CVE are different, even though they belong to the same drug class. Given the relatively small number of zolendronate users and other N-BPs, we were not able to test this hypothesis. Further study with larger sample size of N-BPs is warranted.
Confounding by indication affects the validity of pharmacoepidemiology studies, thus
we performed an analysis to evaluate if the cardiac-protective association was observed for two other anti-osteoporosis medications with a different mechanism-of-action.
These medications were associated with a non-significant or non-robust increased CVE risk (Table 3) , especially for strontium ranelate that has been shown to be associated with increased CVE risk. Such a finding could be due to our limited sample size, or the null association, which was reported in two large population-wide studies. Our study has several strengths. To the best of our knowledge, this is the first large contemporary analysis of real-world clinical practice to compare the risk of CVE among hip fracture patients with and without anti-osteoporosis treatment, and complements results from RCTs. All records in the CDARS were validated with high accuracy, (47) and is a powerful platform from which to conduct large-scale, postmarketing, drug surveillance studies. (16, 17, 48, 49) This study was also carefully designed.
Patients with previous exposure to anti-osteoporosis treatment were excluded to avoid a residual effect of treatment. Similarly, patients with history of hip fracture and cancer were excluded. Using a time-dependent PS matching method, the potential confounding factors between treated and untreated groups were minimized, and we included multiple sensitivity analyses to further reduce the confounding bias. Immortal bias due to delay of treatment was adjusted using the robust method.
There were several limitations in the current study. First, similar to other studies utilised healthcare record, over-the-counter products by a non-HA pharmacy are not captured by the CDARS. Nonetheless, patients with chronic diseases who require long-term treatment commonly use the service of HA because the medication cost is highly subsidized. Therefore, the impact of uncaptured medications should be minimal.
Second, although we excluded patients with prescription records two-year prior to hip fracture, the residual effect of anti-osteoporosis medication may exceed this time although the effect should be minimal. Third, the effect of bone mineral density (BMD)
on CVE is unknown. One would expect that patients with a lower BMD would be likely to be prescribed anti-osteoporosis treatment. Nonetheless, it is known that low BMD is associated with higher CVE risk. Therefore, even if BMD affects treatment decisions, it would have led to under-estimation, not over-estimation, of the treatment effect.
Fourth, data were not available on body mass index, blood pressure, blood lipids and smoking, which are risk factors for CVEs. To address the concern, we included the diagnoses of overweight and obesity, hypertensive diseases, and hyperlipidaemia in the PS model as surrogate markers of these factors. However, residual bias is still a possible.
Similarly, other potential confounding factors are not captured in CDARS, such as emigration, vitamin D and calcium supplementation use. However, it is expected that these confounding factors may not confer large effects on the clinical outcomes, especially in a short period of time (e.g. 1-year cardiovascular mortality, MI, and stroke).
In conclusion, osteoporosis is under-treated among hip fracture patients. The use of alendronate was associated with a reduced risk of cardiovascular mortality, MI and 
